ArticleJournal of cachexia, sarcopenia and muscle2023
Fatty acid amides as potential circulating biomarkers for sarcopenia.
Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Association of handgrip strength with the plasma metabolomic profile: secondary analysis of a protein intervention study.Metabolomics : Official journal of the Metabolomic Society · 2026Trial
- Integrated Proteomic and Metabolomic Profiling for Developing Novel Plasma-Based Diagnostic Models of Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2026Article
- Amino acid metabolites as potential circulating biomarkers for sarcopenia.Scientific reports · 2025Article
- Sarcosine shows promise in preventing sarcopenia.Nature aging · 2025Article
- Towards Precision in Sarcopenia Assessment: The Challenges of Multimodal Data Analysis in the Era of AI.International journal of molecular sciences · 2025Review
- Genetic determinants of muscle health: A population-based study.The Journal of frailty & aging · 2025Article
- Carnitine Metabolite as a Potential Circulating Biomarker for Sarcopenia in Men.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Causal Relationship Between Circulating Metabolites and Sarcopenia-Related Traits: A Mendelian Randomization and Experimental Study.Food science & nutrition · 2025Article
- Molecular Profiling of Inflammatory and Myofibroblast Cancer-Associated Fibroblast Subtypes Derived from Human Pancreatic Stellate Cells Using Machine Learning-Based Label-Free Raman Spectroscopy.Biomaterials research · 2025Article
- Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men.Journal of cachexia, sarcopenia and muscle · 2024Article
- Aging-Related Sarcopenia: Metabolic Characteristics and Therapeutic Strategies.Aging and disease · 2024Review
- Association between Vitamin D Deficiency and Clinical Parameters in Men and Women Aged 50 Years or Older: A Cross-Sectional Cohort Study.Nutrients · 2023Article
- Fatty acid amides as potential circulating biomarkers for sarcopenia.Journal of cachexia, sarcopenia and muscle · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is characterized by a progressive decrease in skeletal muscle mass and function with age. Given that sarcopenia is associated with various metabolic disorders, effective metabolic biomarkers for its early detection are required. We aimed to investigate the metabolic biomarkers related to sarcopenia in elderly men and perform experimental studies using metabolomics.
methodsPlasma metabolites from 142 elderly men, comprising a sarcopenia group and an age-matched control group, were measured using global metabolome profiling. Muscle and plasma samples from an aging mouse model of sarcopenia, as well as cell media and cell lysates during myoblast differentiation, were analysed based on targeted metabolome profiling. Based on these experimental results, fatty acid amides were quantified from human plasma as well as human muscle tissues. The association of fatty acid amide levels with sarcopenia parameters was evaluated.
resultsGlobal metabolome profiling showed that fatty acid amide levels were significantly different in the plasma of elderly men with sarcopenia (all Ps < 0.01). Consistent with these results in human plasma, targeted metabolome profiling in an aging mouse model of sarcopenia showed decreased levels of fatty acid amides in plasma but not in muscle tissue. In addition, the levels of fatty acid amides increased in cell lysates during muscle cell differentiation. Targeted metabolome profiling in men showed decreased docosahexaenoic acid ethanolamide (DHA EA) levels in the plasma (P = 0.016) but not in the muscle of men with sarcopenia. DHA EA level was positively correlated with sarcopenia parameters such as skeletal muscle mass index (SMI) and handgrip strength (HGS) (P = 0.001, P = 0.001, respectively). The area under the receiver-operating characteristic curve (AUC) for DHA EA level ≤ 4.60 fmol/μL for sarcopenia was 0.618 (95% confidence interval [CI]: 0.532-0.698). DHA EA level ≤ 4.60 fmol/μL was associated with a significantly greater likelihood of sarcopenia (odds ratio [OR]: 2.11, 95% CI: 1.03-4.30), independent of HGS. The addition of DHA EA level to age and HGS significantly improved the AUC from 0.620 to 0.691 (P = 0.0497).
conclusionsOur study demonstrated that fatty acid amides are potential circulating biomarkers in elderly men with sarcopenia. DHA EA, in particular, strongly related to muscle mass and strength, can be a key metabolite to become a reliable metabolic biomarker for sarcopenia. Further research on fatty acid amides will provide insights into the metabolomic changes relevant to sarcopenia from an aging perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.